JVA, an isoniazid analogue, is a bioactive compound against a clinical isolate of the Mycobacterium avium complex

Bacteria belonging to Mycobacterium avium complex are organisms of low pathogenicity that infect immunosuppressed individuals. Infection is treated with an antimicrobial macrolide, Clarithromycin (CAM) or Azitromycin, associated with Ethambutol and Rifabutin during 12 months. Regimen long duration a...

Full description

Saved in:
Bibliographic Details
Published inTuberculosis (Edinburgh, Scotland) Vol. 115; pp. 108 - 112
Main Authors Fahel, Júlia S., Vieira, Rafael P., Marinho, Fábio V., Santos, Viviane C., de Assis, João Vitor, Corsetti, Patrícia P., Ferreira, Rafaela S., de Almeida, Mauro V., Oliveira, Sergio C.
Format Journal Article
LanguageEnglish
Published Scotland Elsevier Ltd 01.03.2019
Elsevier Science Ltd
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Bacteria belonging to Mycobacterium avium complex are organisms of low pathogenicity that infect immunosuppressed individuals. Infection is treated with an antimicrobial macrolide, Clarithromycin (CAM) or Azitromycin, associated with Ethambutol and Rifabutin during 12 months. Regimen long duration and side effects hinder patient's commitment to treatment favoring emergence of antibiotic resistance. In this present study, we evaluated the activity of JVA, an Isoniazid (INH) derivative, against M. avium 2447, a clinical isolate. We demonstrated that JVA reduces M. avium 2447 growth in macrophages, more efficiently than CAM and INH. In order to explore JVA mechanism of action, we investigated compound properties and performed pH-dependent stability studies. Our results suggest an enhanced ability of JVA to cross biological membranes. Furthermore, we suggest that in acidic conditions of macrophages' phagosomes, where mycobacteria replicate, JVA would be promptly hydrolyzed to INH, delivering the adduct INH-nicotinamide adenine dinucleotide and thus inhibiting M. avium 2447 growth.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1472-9792
1873-281X
DOI:10.1016/j.tube.2019.03.002